Helicobacter pylori Research in Human Health

A special issue of Gastrointestinal Disorders (ISSN 2624-5647).

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 2773

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy
Interests: study of microbial survival strategies (biofilm, non-cultivable vital state), evaluation of antimicrobial, anti-biofilm and anti-virulence activities of bioactive substances of natural origin; semi-synthesis and innovative biomaterials; the research activity has concerned oral cavity microorganisms; Helicobacter pylori and microorganisms related to chronic wounds (Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans) and lung infections (Mycobacterium abscessus and other fast-growing mycobacteria)
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, Italy
Interests: antimicrobial; anti-biofilm and anti-virulence activities of natural compounds alone and combined with antibiotics against multi drug-resistant strains (Helicobacter pylori, Staphylococcus spp., Pseudomonas aeruginosa, Candida albicans, Mycobacterium abscessus and other fast-growing mycobacteria)
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy
2. Clinical Microbiology and Virology Unit, Careggi University Hospital, 50139 Florence, Italy
Interests: antimicrobial resistance; rapid clinical microbiology; diagnostic stewardship; carbapenem-resistant Gram-negatives; oxazolidinone-resistant Gram-positives
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori is a bacterial gastroduodenal pathogen colonizing around 50% of the world population, representing the main cause of chronic gastritis, peptic ulcer disease and gastric cancer.

The IARC classified H. pylori as a type I carcinogen, recommending the treatment of its infection when the bacterium is diagnosed to prevent gastric cancer.

The development of Anti-H.pylori treatment strategies remain a challenge due its high antibiotic resistance; the WHO listed this bacterium among the pathogens for which increasing antibiotic resistance represents a serious threat for human health.

In addition, H. pylori is able to evade and manipulate the host immune system and establish chronic infection, producing biofilms and entering into a dormant state, inducing a tolerant state against antimicrobial drugs. Innovative therapies are thus needed, such as natural substances associated with drugs commonly used in therapy, which demonstrate a capability to act as antibiotic resistance breakers, probiotics, human-derived-peptides and photodynamic therapy, which are well-described in the literature.

 

This Special Issue will focus on the latest advances in innovative treatments  for H. pylori’s eradication.

Topics of interest include, but are not limited to, the following:

  • Antibiotic resistance breakers in pylori treatment;
  • New strategies against pylori biofilms and dormancy state;
  • New synergic natural compounds/antibiotic association in pylori treatment.

Dr. Mara Di Giulio
Dr. Silvia Di Lodovico
Dr. Alberto Antonelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Helicobacter pylori
  • biofilm and vBNC state
  • innovative antimicrobial strategies
  • anti-virulence action

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 1450 KiB  
Article
Evaluation of Accuracy and Feasibility of a New-Generation Ultra-Rapid Urease Test for Detection of Helicobacter pylori Infection
by Marco Cagnoni, Cristiano Pagnini, Marco Crovaro, Antonio Aucello, Riccardo Urgesi, Lorella Pallotta, Gianfranco Fanello, Maria Carla Di Paolo and Maria Giovanna Graziani
Gastrointest. Disord. 2022, 4(3), 205-213; https://doi.org/10.3390/gidisord4030019 - 26 Aug 2022
Cited by 2 | Viewed by 2304
Abstract
Helicobacter pylori (Hp) infection can be diagnosed by invasive and noninvasive methods, and, among the former, Rapid Urease Tests (RUTs) are an important option. Accuracy and rapidity of results are fundamental for RUTs. The aim of the study is to prospectively evaluate the [...] Read more.
Helicobacter pylori (Hp) infection can be diagnosed by invasive and noninvasive methods, and, among the former, Rapid Urease Tests (RUTs) are an important option. Accuracy and rapidity of results are fundamental for RUTs. The aim of the study is to prospectively evaluate the sensitivity, specificity and time to positivity of a new-generation ultra-rapid urease test (iNatal duo test) for Hp detection and compare the results with other available RUTs [CLO Test (Campylobacter-Like Organism Test), CP Test (Campylobacter pylori Test) and Pronto Dry]. Gastric biopsies were taken in consecutive patients undergoing upper endoscopy: two in the antrum and two in the body for histology, and one in the antrum and one in the body for each RUT. RUTs were read at 1, 5, 15, 30 and 60 min, 3 h and 24 h after biopsy insertion into the reagent. Histology was considered as “gold standard”. The performance of the tests was evaluated in patients not taking proton pump inhibitors (PPI) (n = 924) by calculation of sensitivity, specificity and positive and negative predictive value. Agreement rate (κ) for every RUT and histology was calculated and compared. The performance of the iNatal duo test was also tested in a subgroup of patients taking PPI (n = 198). Hp was positive in 225/924 patients (24.3%) not taking PPIs and in 56/198 (28.3%) who were taking PPIs. The iNatal duo test was more sensitive than the other RUTs for detecting Hp at every time point. The sensitivity at 5 min was 96.2% in patients not taking PPIs and 92.2% in patients taking PPIs. κ with histology was higher for the iNatal duo test than any other RUT (at 30 min: iNatal duo 0.99, CLO 0.60, CP 0.78, Pronto 0.85, at 15 min: iNatal duo 0.99, CLO 0.46, CP 0.63, Pronto 0.71). In a prospective study, the iNatal duo test demonstrated high accuracy and rapidity for Hp detection, both in patients with and without PPI therapy. This new generation of ultra-rapid urease test could be useful for the rapid and correct management of patients undergoing upper GI endoscopy for suspected Hp infection. Full article
(This article belongs to the Special Issue Helicobacter pylori Research in Human Health)
Show Figures

Figure 1

Back to TopTop